(NASDAQ: NAMS) Newamsterdam Pharma Co Nv's forecast annual revenue growth rate of 31.52% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 55.38%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.2%.
Newamsterdam Pharma Co Nv's revenue in 2025 is $52,966,292.On average, 5 Wall Street analysts forecast NAMS's revenue for 2025 to be $1,541,700,937, with the lowest NAMS revenue forecast at $334,566,617, and the highest NAMS revenue forecast at $2,413,819,556. On average, 1 Wall Street analysts forecast NAMS's revenue for 2026 to be $668,010,528, with the lowest NAMS revenue forecast at $668,010,528, and the highest NAMS revenue forecast at $668,010,528.
In 2027, NAMS is forecast to generate $14,618,315,769 in revenue, with the lowest revenue forecast at $4,048,480,613 and the highest revenue forecast at $28,231,584,438.